share_log

CORRESP: CORRESP

CORRESP: CORRESP

CORRESP:信函
美股SEC公告 ·  2024/04/17 22:18

Moomoo AI 已提取核心訊息

Adial Pharmaceuticals, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-3, initially filed on April 12, 2024. The company seeks to have the registration become effective on April 19, 2024, at 5:00 p.m. Eastern Time, or as soon as possible thereafter. This request was communicated in a letter to the SEC, highlighting the company's acknowledgment of its obligations under federal securities laws regarding the issuance of securities covered by the statement. Adial Pharmaceuticals has designated Leslie Marlow and Hank Gracin of Blank Rome LLP with the authority to modify or withdraw the acceleration request if necessary.
Adial Pharmaceuticals, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-3, initially filed on April 12, 2024. The company seeks to have the registration become effective on April 19, 2024, at 5:00 p.m. Eastern Time, or as soon as possible thereafter. This request was communicated in a letter to the SEC, highlighting the company's acknowledgment of its obligations under federal securities laws regarding the issuance of securities covered by the statement. Adial Pharmaceuticals has designated Leslie Marlow and Hank Gracin of Blank Rome LLP with the authority to modify or withdraw the acceleration request if necessary.
Adial製藥公司已正式要求美國證券交易委員會(SEC)加快其最初於2024年4月12日提交的S-3表格註冊聲明的生效日期。該公司力求使註冊於美國東部時間2024年4月19日下午 5:00 生效,或此後儘快生效。該請求是在給美國證券交易委員會的一封信中傳達的,信中強調了該公司承認其根據聯邦證券法承擔的有關該聲明所涵蓋證券發行的義務。Adial Pharmicals已指定Blank Rome LLP的萊斯利·馬洛和漢克·格拉辛有權在必要時修改或撤回加速請求。
Adial製藥公司已正式要求美國證券交易委員會(SEC)加快其最初於2024年4月12日提交的S-3表格註冊聲明的生效日期。該公司力求使註冊於美國東部時間2024年4月19日下午 5:00 生效,或此後儘快生效。該請求是在給美國證券交易委員會的一封信中傳達的,信中強調了該公司承認其根據聯邦證券法承擔的有關該聲明所涵蓋證券發行的義務。Adial Pharmicals已指定Blank Rome LLP的萊斯利·馬洛和漢克·格拉辛有權在必要時修改或撤回加速請求。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息